MarketClub Options Trading
Rockwell Trading Coaching
Rockwell Trading Mentoring
INO TV Trading Education
Free Options Trading Education
INO TV Videos
CELG Breakout Entry Signals Technical Analysis
Intermediate-Term Technical Analysis
Moving Average Convergence/Divergence (MACD) indicates a Bearish Trend. Chart pattern indicates a Strong Downward Trend. Relative Strength is Neutral. Up/Down volume pattern indicates that the stock is under Distribution. The 50 day Moving Average is rising which is Bullish. The 200 day Moving Average is rising which is Bullish. Price is above Support of 50.02 which is Bullish. Watch for resistance at 51.67.
For coaching advice in determining the proper criteria to enter and exit a specific position, visit the Rockwell Trading Coaching Program. A free 60-minute one-on-one session is available to interested investors.
Company Business Summary (Sabrient Systems)
COMPANY PROFILE. Celgene Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of innovative therapies to treat cancer and immune-inflammatory related diseases in Europe and the United States. Celgene Corporation was incorporated in 1986 as a Delaware corporation. The Company is a multi-national integrated biopharmaceutical Company primarily engaged in the discovery, development and commercialization of innovative therapies designed to treat cancer and immune-inflammatory-related diseases. The Company had total revenue of $536.9 million and net income of $63.7 million for the year ended December 31, 2005. The Company is dedicated to innovative research and development designed to bring new therapies to market. The Company is involved in research in several scientific areas that may deliver proprietary next-generation therapies, such as cellular signaling biology, immunomodulation and placental stem cell research. The drugs the Company develops are designed to treat life-threatening diseases or chronic debilitating conditions where patients are poorly served by current therapies. Building on its growing knowledge of the biology underlying hematological and solid tumor cancers, the Company is investing in a range of innovative therapeutic programs that are investigating ways to attack the disease source through multiple mechanisms of action and intracellular pathways. The Company's commercial programs include pharmaceutical sales of REVLIMID, THALOMID, and ALKERAN and sales of FOCALIN to Novartis Pharma AG, or Novartis. REVLIMID is an oral immunomodulatory drug recently granted approval by the FDA for the treatment of patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities, or MDS, with the 5q chromosomal deletion. REVLIMID is being distributed through contracted pharmacies. THALOMID was approved by the FDA in July 1998 for the treatment of acute cutaneous manifestations of moderate to severe erythema nodosum leprosum, or ENL, an inflammatory complication of leprosy. THALOMID is widely prescribed off-label for treating multiple myeloma and other cancers. Enterprise Value $22.47 Billion P/E (Trailing) 158.4 Dividend $0 Dividend Yield 0 % 5-year Historical EPS Growth Rate -- Liquidity Ratio $196,574 Shares Outstanding 382.73 Million Employees 1,287 1. Jaywalk operates a network of Independent Research Providers who post stock reports and recommendations to the Jaywalk platform.
Earnings and Revenue Update: For the quarter ended June 30, 2007, Celgene reported earnings of $54.9 million or $0.13 per share compared with $57.4 million or $0.14 per share for the prior quarter and $9.6 million or $0.03 per share for the same quarter one year ago. Revenues were $347.9 million for the quarter ended June 30, 2007 compared with $293.4 million for the prior quarter and $197.2 million for the same quarter one year ago. Last twelve months' earnings were $0.38 per share compared with $0.08 per share a year ago. Last twelve months' revenues were $1.2 billion compared with $657.9 million a year ago.